Application of LDH assay for therapeutic efficacy evaluation of ex vivo tumor models by Cox, Megan C. et al.
1
Vol.:(0123456789)
Scientific Reports |        (2021) 11:18571  | https://doi.org/10.1038/s41598-021-97894-0
www.nature.com/scientificreports
Application of LDH assay 
for therapeutic efficacy evaluation 
of ex vivo tumor models
Megan C. Cox1,7, Rita Mendes2,3,7, Fernanda Silva4, Teresa F. Mendes2,3, Adelyn Zelaya‑Lazo1, 
Kathleen Halwachs1, Julie J. Purkal1, Inês A. Isidro2,3, Ana Félix4,5, Erwin R. Boghaert1 & 
Catarina Brito2,3,6*
The current standard preclinical oncology models are not able to fully recapitulate therapeutic 
targets and clinically relevant disease biology, evidenced by the 90% attrition rate of new therapies 
in clinical trials. Three‑dimensional (3D) culture systems have the potential to enhance the relevance 
of preclinical models. However, the limitations of currently available cellular assays to accurately 
evaluate therapeutic efficacy in these models are hindering their widespread adoption. We assessed 
the compatibility of the lactate dehydrogenase (LDH) assay in 3D spheroid cultures against other 
commercially available readout methods. We developed a standardized protocol to apply the 
LDH assay to ex vivo cultures, considering the impact of culture growth dynamics. We show that 
accounting for growth rates and background release levels of LDH are sufficient to make the LDH 
assay a suitable methodology for longitudinal monitoring and endpoint assessment of therapeutic 
efficacy in both cell line‑derived xenografts (xenospheres) and patient‑derived explant cultures. This 
method has the added value of being non‑destructive and not dependent on reagent penetration 
or manipulation of the parent material. The establishment of reliable readout methods for complex 
3D culture systems will further the utility of these tumor models in preclinical and co‑clinical drug 
development studies.
The current failure rate of new therapies in clinical trials is approximately 90%1. This high attrition rate, largely 
attributed to a lack of therapeutic efficacy, is a major factor driving the generation and implementation of clini-
cally relevant models in drug discovery and development. The absence of such models has been suggested as a 
major reason why ineffective therapies reach clinical  trials2. Because traditional preclinical model systems fail to 
reflect the complexity of human cancer, models that mimic the histiotypic tumor composition could represent 
greater physiological relevance than individually cultured cancer cells. In this regard, three-dimensional (3D) 
in vitro and ex vivo cultures may be more relevant to the clinic, while still maintaining the readability of reduc-
tionist approaches that study the cancer cell out of its physiological context.
The neoplastic tumor is composed of cancer cells comingled with a microenvironment containing an extracel-
lular matrix (ECM), stromal cells, and a multitude of signaling factors capable of regulating therapeutic response 
across cancer  types3–6. Microenvironmental components play a role in drug resistance and cancer  progression7. 
Mechanisms of microenvironmentally-driven resistance include inhibition of drug tumor penetration, signaling 
pathway redundancy, and the presence of signaling factors that alter cancer cell behavior. Traditional monolayer 
screening platforms lack most microenvironmental components. Additionally, a complete understanding of the 
role tumor stroma plays in therapeutic efficacy is restricted by the limited capacity of standard in vitro model sys-
tems to only mimic the interactions between cancer cells and a select few components of the  microenvironment8. 
Ex vivo models derived from xenografts or patient tumors incorporate the complexity of the parent tumor 
microenvironment into a preclinical system, namely tumor architecture and cancer cell-stromal cell  interactions9.
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Limitations to reliably assess therapeutic efficacy in these models by means of currently available cellular 
assays have so far impeded their widespread adoption in the drug development cascade. Standard readout 
methods include assays for cytotoxicity, proliferation, drug binding, apoptosis, and adenosine triphosphate 
(ATP) levels. Each come with their own inherent limitations that vary depending on cell type, cell number, and 
culture complexity. The simple addition of a 3D architecture can introduce reagent penetration  limitations10. 
The incorporation of multiple cell types can further confound the determination of therapeutic efficacy by the 
inability of assays to distinguish between drug-induced cell death in cancer vs stromal  cells11. It is therefore cru-
cial to validate readout methods in complex culture formats, considering the advantages and limitations of each 
technique, and to create protocols for preclinical drug screening studies employing in vitro and ex vivo tumor 
models that are standardized, reproducible, and applicable to the culture system of  choice12.
We have generated cultures from cell line-derived xenografts, termed xenospheres, and patient samples from 
surgical resection, termed patient-derived explants (PDE). The purpose of this study was to provide guidance 
on the application of the lactate dehydrogenase (LDH) assay for longitudinal monitoring and endpoint analysis 
of therapeutic efficacy in these complex culture models, where sample availability is highly limited. The LDH 
assay is suitable for longitudinal monitoring of cultures when employed to quantify the leakage of LDH from 
damaged cells to the culture supernatant. The assay does not require manipulation of the parent material, such 
as fluorescent labeling or gene transduction. It is not dependent on reagent penetration and, overall, is a non-
destructive readout, making it compatible and highly attractive for PDE culture formats. The utility of the LDH 
assay was assessed in non-small cell lung cancer (NSCLC) 3D spheroid and xenospheres cultures against other 
longitudinal and non-longitudinal standard readout methods, including volume measurements, luminescence 
measurements of luciferase-expressing cells, and the CellTiter-Glo 3D (CTG-3D) assay. We then demonstrate 
that the LDH assay can assess the therapeutic efficacy of chemotherapeutics in ovarian cancer PDE (OvC-PDE) 
cultures.
Results
LDH assay reproducibility and precision is equivalent to other readouts commonly employed 
in 3D cell cultures. To determine whether the LDH assay can reliably assess cell growth and viability in 3D 
cultures, we compared the LDH assay to other established readout techniques commonly used to quantitatively 
measure cell viability in 3D cultures. Other criteria considered in the selection of readouts to directly compare 
the LDH assay include methods that are (1) compatible with low cell numbers due to the labor-intensive process 
of xenosphere generation and limited availability of patient material making methods requiring high cell num-
bers unfeasible in these culture formats; (2) do not require generation of single cell suspensions as the cell line 
and cell status may present distinct sensitivity to dissociation affecting assay results; (3) do not require sectioning 
(physical or optical) of the sample to capture the signal over the larger area of the xenospheres (~ 500–600 µm 
diameter) and PDE (1–2 mm diameter) which would involve a more complex experimental procedure and data 
processing.
We used spheroids of NCI-H1650 cells, as their generation is highly reproducible and a bioluminescent variant 
of the cells (NCI-H1650.LMC) is available, making the culture particularly suited to our purpose. NCI-H1650 and 
NCI-H1650.LMC spheroids, generated by seeding 2500, 5000, 7500, 10,000, 12,500, and 15,000 cells in ultra-low 
attachment round bottom plates, were evaluated via volume, CTG-3D, LDH, and luminescence, on day 0 and 7 
of culture (Fig. 1). PrestoBlue and MTS assays were also evaluated but reagent penetration limitations resulted in 
their elimination as suitable options for universal assessment of viability in 3D cultures (Supplementary Fig. 1A, 
B). In contrast, discernment between seeding densities was not limited by reagent penetration in the LDH and 
CTG-3D assays (Supplementary Fig. 1C, D). Each readout could measure 5000-cell differences between seed-
ing density on day 0, and each readout detected cell growth from day 0 to 7, except for luminescence that did 
not detect significant differences between day 0 and day 7 for seeding densities of 12,500 and 15,000 cells per 
well (Fig. 1A–E and Supplementary Tables 1–3). This might indicate a limitation of the luminescence readout 
to accurately report cell content as culture size increases, which may be due to diffusion limitations. In LDH 
measurements, saturation occurred at higher cell densities on day 7, but this could be overcome in future assays 
by diluting samples prior to analysis. The most sensitive readout to determine cell growth was volume, which 
together with LDH and CTG-3D, detected differences in cell content across all seeding densities (Fig. 1A–E 
and Supplementary Tables 1–3). However, the comparison of data sets via Pearson correlation analysis showed 
a strong correlation (R2 > 0.9) between volume measurements and all other readout methods, including LDH 
(Fig. 1F).
Culture dynamics alter LDH assay data analysis. Longitudinal monitoring is a significant benefit of 
the LDH assay. However, differences in culture growth dynamics, including growth rate, death rate, and back-
ground LDH release in control and treated samples, may impact assessments of therapeutic efficacy. LDH data 
was simulated to ascertain how these factors might affect the determination of cell death (Fig. 2). Simulations 
represent drug-induced cell death calculated from LDH measurements in cases of no cell growth or cell tripling 
over the culture period (300% cell growth) and the presence of no background release or 10% background 
release, during treatment that induces 0–80% cell death over a 7-day culture period. Generally, the calculation 
of drug-induced death by LDH assay takes into consideration the amount of LDH that leaked to the culture 
medium in the treated group (conditioned medium, CM) and assumes the total cell content is equal in the 
treated and control groups (Eq. 3). The LDH content of the cell lysate can then be determined only for a control 
group and the percentage of drug-induced cell death defined as in Eq. (3). This assumption allows for the deter-
mination of cell death during longitudinal measurements at intermediate timepoints without sacrificing treated 
group samples. However, as shown in Fig. 2A,B, calculations based on CM LDH readings (Eqs. 3 and 4) are most 
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Figure 1.  LDH assay reproducibility and precision in 3D culture is equivalent to alternate readout methods. 
(A) Lactate dehydrogenase (LDH) content, (B) CellTiter-Glo 3D (CTG-3D), (C) volume, and (D) luminescence 
measurements were collected from NCI-H1650 and/or NCI-H1650.LMC spheroids generated by seeding 
2500, 5000, 7500, 10,000, and 12,500 cells per well of ultra-low attachment round bottom plates. LDH content 
and volume measurements were collected from both NCI-H1650 and NCI-H1650.LMC spheroids, CTG-3D 
readings were collected from NCI-H1650 spheroids only, and luminescence readings were collected from NCI-
H1650.LMC spheroids only. Statistics for data presented in (A–D) is summarized in Supplementary Tables 1–3. 
(E) Growth rates for each seeding density condition calculated from cell content determined by each readout 
method was normalized to the growth rate determined from volume measurements. (F) Pearson correlation 
coefficient between volume and LDH, CTG-3D, and luminescence measurements (data are presented as 
mean ± SD of N = 5, *p < 0.05, **p < 0.01, ***p < 0.001).
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accurate if there is no background LDH released by the cells. In cases where background release occurs, drug-
induced cell death is underestimated as LDH content in the CM of the control sample will continue to increase 
throughout the culture, resulting in a disproportionate comparison of LDH content in the CM of treated to 
control samples (Fig. 2A,B). Thus, the determination of drug-induced cell death based on LDH content of the 
cell lysate (Eq. 5, Fig. 2C) is most accurate, as it considers the LDH content of live cells present in the treated 
and control group, and background release is not considered. For the selected therapeutic efficacy range, culture 
growth dynamics do not appear to impact the determination of cell death using any analysis method. However, 
for higher death rates (Supplementary Fig. 2A), Eqs. (3) and (4) can again underestimate cell death. In this case, 
frequent longitudinal measurements are necessary for accurate stack ranking using Eqs. (3) and (4).
LDH assay can effectively assess standard‑of‑care (SOC) efficacy in xenosphere cul‑
tures. Xenospheres were generated from xenograft tumors grown in mice. The generation of these cultures 
is fully described in the “Methods” section and illustrated in Fig. 3. Characterization by hematoxylin and eosin 
(H&E) is presented in Supplementary Fig. 3. We treated NCI-H1650 and NCI-H1650.LMC xenospheres with 
0.1, 5, 25, 125, 625, and 3125 nM of the SOC, Docetaxel (DTX). Culture viability was assessed via LDH assay 
and compared with volume, CTG-3D, and luminescence measurements (Fig. 4A). For the LDH assay in Fig. 4A, 
Figure 2.  Culture growth dynamics impact how LDH data should be analyzed to evaluate therapeutic efficacy. 
Simulations represent cases in which a therapy that induces 0–80% cell death over the 7-day culture period has 
been applied to cultures that have 10% or no background LDH and do not grow or cell number triples over the 
culture period. Drug-induced cell death was calculated employing Eq. (3) (A), Eq. (4) (B) or Eq. (5) (C).
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culture viability was determined following Eq. (5), as the xenospheres cultures release 8.5% ± 2.8 of background 
LDH and grow over the 7-day culture period (Supplementary Fig. 2Bi). Utilizing Eqs. (3) or (4) to analyze the 
LDH assay data would underestimate the drug-induced cell death due to the dynamics of the xenosphere culture 
(Supplementary Fig. 4). The IC50 values, as determined by each readout method, were within the same order of 
magnitude (Fig. 4B). Pearson correlation analysis showed a strong correlation (R2 > 0.9) between the LDH assay 
and all other readout methods (Fig. 4C).
Variations in OvC‑PDE response to SOC chemotherapy captured by LDH assay. OvC patients 
usually undergo surgery followed by adjuvant chemotherapy, consisting of a combination of carboplatin and 
paclitaxel (C + P). Sixteen OvC samples from different subtypes were enrolled in this study and processed as 
described in the “Methods” section and illustrated in Fig. 3. Clinical-pathological parameters related to these 
tumors are reported in detail in Supplementary Tables 7 and 8. We previously developed an OvC-PDE  model13 
in which tumor architecture and cell type heterogeneity are preserved for at least 1 month in culture. This culture 
strategy can be broadly applied for the culture of different OvC  types13. Here, we downscale this model to allow 
for simultaneous efficacy testing of multiple drugs. The 10 PDE/well scale was selected since cell viability was 
maintained after the 7-day adaption to culture period, and tumor architecture, cell phenotype, proliferation and 
apoptosis levels of the original tumor were also retained throughout 21 days in culture, similar to what we have 
previously  described13 (Supplementary Figs. 5A,B and 6 and Supplementary Table 9).
We asked if patient-specific and time-dependent variations in drug response would be captured by the LDH 
assay in a setup of long-term drug challenge of OvC-PDE cultures, with repeated evaluation of the same culture 
well over several cycles of chemotherapy. We challenged OvC-PDE cultures derived from 13 patients with two 
cycles of SOC or single-agent chemotherapy, over 2 weeks of culture (Fig. 3). Drug-induced cell death was evalu-
ated by the LDH assay after each cycle of therapy. Having established that OvC-PDE did not grow over the culture 
period (Supplementary Fig. 2Bii), the drug-induced cell death could be calculated by an adaptation of Eq. (3), in 
which the two cycles of chemotherapy are taking into account (Eq. 6, as described in the “Methods” section). This 
implied that only control conditions needed to be lysed, so the explants exposed to the drugs could be observed 
over time, after the first and second drug cycles. Therefore, we could rank SOC and single agent efficacy among 
OvC-PDE derived from different patients, while preserving the biological material. For most OvC-PDE cultures, 
the first drug cycle was more effective than the second (Supplementary Fig. 7). The mean drug-induced cell death 
after two drug cycles, and its variability, changes with each treatment (Fig. 5A). Carboplatin induced the lowest 
Figure 3.  Schematic representation of the culture generation and drug cycle strategy pursued for ex vivo 
cultures. (A) Mouse xenografts are mechanically dissociated to form xenosphere explants. Individual 
xenospheres are cultured in a single well of a 96-well ultra-low attachment (ULA) plate. Docetaxel (DTX) 
treatments of 0.1, 5, 25, 125, 625, and 3125 nM are added directly to the xenospheres on the day of culture 
generation. Cell death in xenosphere cultures is assessed on day 7 by LDH assay. (B) Surgical-resected ovarian 
tumor specimens are mechanically dissociated into fragments, named patient-derived explants (PDE) and 
cultured in 12-well plates at a concentration of 5 PDE/ml, under orbital agitation at 100 rpm. After a 7-day 
adaptation to culture period, PDE cultures are challenged weekly with standard-of-care (SOC) chemotherapy, 
namely carboplatin (25 mg/ml) or paclitaxel (10 mg/ml) as single agents or in combination. Cell death is 
assessed longitudinally (day 7, 14, and 21 of culture) by LDH assay.
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response in terms of cell death (10.0% ± 7.8), followed by paclitaxel (17.4% ± 10.5) and the SOC chemotherapy 
(25.5% ± 12.6). The greatest response variation was observed after SOC chemotherapy treatment (Fig. 5A,C).
To further analyze the effect of combination therapy, we compared the combination effect (C + P) with the 
most efficacious single agent, henceforth referred to as the highest single agent (HSA)14 (Fig. 5B,C). In OvC7, 
OvC13, and OvC14, the HSA was carboplatin, whereas for the other cases, it was paclitaxel (Fig. 5B,C). We 
observed a negative combination effect (fold change, FC < 1), meaning the combination was less efficacious 
than the HSA, in 4 out of 13 (31%) OvC-PDE cases. These four cases correspond to samples derived from 
high-grade serous carcinoma (HGSC, OvC5, OvC8, OvC11 and OvC16). Additionally, OvC11 and OvC8 were 
the overall lowest responders to the combination treatment, with 4.5% ± 2.0 and 10.8% ± 0.8 drug-induced cell 
death, respectively (Fig. 5B,C and Supplementary Fig. 7). In one (8%) case (OvC14), the drug combination 
was as effective as the HSA (FC = 1). In the remaining eight (61%) cases, we observed a positive combination 
effect (FC > 1), meaning the combination was more efficacious than the HSA. OvC2, OvC4, OvC10, and OvC12 
presented a FC ranging from 1.3 to 1.7 and were derived from HGSC, low-grade serous carcinoma (LGSC) and 
endometrioid carcinoma samples. The remaining four cases (OvC7, OvC9, OvC13 and OvC15) had a FC greater 
than 2 and were derived from sex-cord stromal, borderline ovarian tumors and HGSC (Fig. 5C). No correlation 
was observed between the drug combination-induced cell death and the FC of the combination to the HSA 
(Pearson correlation of R2 = 0.3).
To validate the LDH assay as a measure of overall cell death (Fig. 6A) in PDE culture, we compared it with 
other readout methods currently used on primary patient samples in the clinic, namely H&E for tumor and 
stroma quantification and immunohistochemistry (IHC) analysis for evaluation of proliferation and apoptosis 
levels (Fig. 6, Supplementary Figs. 8 and 9, Supplementary Table 10). H&E staining revealed changes in histology, 
denoting differences in viable and necrotic areas and in the proportion of epithelial and stromal compartments 
(Supplementary Fig. 8), when comparing untreated and drug challenged explants. After two drug challenges, 
a significant reduction in the epithelial compartment was observed for SOC chemotherapy and carboplatin 
(p = 0.0005) and the same trend for paclitaxel (Fig. 6B). However, comparing the FC between the combination 
effect and HSA, the LDH assay and epithelial compartment ratio analysis do not agree in all cases (Supplementary 
Fig. 10). Moreover, there is a trend toward decreased levels of proliferation and increased levels of apoptosis after 
all drug challenges (Fig. 6C,D). Overall, response variability was best captured using the LDH assay compared 
with H&E and IHC readouts.
Figure 4.  LDH assay can be used to assess DTX efficacy in xenosphere cultures. (A) DTX efficacy in 
xenosphere cultures was assessed via LDH, CTG-3D, and volume in NCI-H1650 xenospheres or luminescence 
in NCI-H1650.LMC xenospheres. (B) IC50 values of DTX in the xenosphere cultures as determined by each 
readout method, (C) Pearson correlation coefficient between measured LDH content in the cultures after DTX 
treatment and luminescence, CTG-3D, and volume measurements (data is presented as mean ± SD of N = 5, 
*p < 0.05 **p < 0.01).
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Discussion
We have demonstrated the utility of the LDH assay to determine therapeutic efficacy in complex 3D cultures, 
namely xenospheres and PDE. Although PDE may recapitulate the clinical pathology, their applicability for 
drug discovery has been hindered by the limited validation and reproducibility of established readout methods 
to determine therapeutic efficacy in these culture  systems15,16. Parameters beyond measures of cell content for 
analysis of therapeutic efficacy also need to be considered as greater complexity is introduced into preclinical 
tumor models.
As the time scale of therapeutic responses is highly variable, analytical methods that are non-invasive and 
allow for repeated observation of dynamic changes within the 3D cell culture are  desirable17. Additionally, many 
efforts are being directed toward the development of in vitro cultures derived from primary patient samples. 
As patient material is highly limited, assays that can preserve samples, either through their compatibility with 
other readout methods or their ability to generate multiple data sets from the same sample, are needed. However, 
Figure 5.  LDH assay can be used to assess SOC chemotherapy and single agent efficacy in PDE. (A) Drug-
induced cell death evaluation of OvC-PDE using LDH assay after 2 drug cycles (data is presented as mean ± SD 
of N = 13–14). (B) Fold change of the combination drug-induced cell death relative to the drug-induced cell 
death of the highest single agent (HSA), i.e., carboplatin for OvC7, OvC13 and OvC14 and paclitaxel for all the 
other OvC cases (N = 13). (C) Patient sample-specific differences in drug response and combination effects is 
captured in the heatmap (organized by highest to lowest fold change of C + P-induced cell death relative to the 
HSA). (OvC: ovarian cancer; C: carboplatin; P: paclitaxel; BOTs: Borderline Ovarian Tumors; AGTC: Adult 
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Figure 6.  Drug-induced cell death variations are better captured by LDH than clinically-utilized endpoint 
readouts. Drug-induced cell death evaluation of OvC-PDE using (A) LDH assay (N = 13), (B) epithelial 
compartment (malignant tumor cells) ratio (N = 12), and (C) proliferation (N = 6–8) and (D) apoptosis (N = 6–9) 
levels. Wilcoxon signed-rank statistical test was applied to compare C + P with untreated condition for all 
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longitudinal determination of growth and viability in complex 3D cultures is challenging as many bioassays are 
developed for two-dimensional (2D) culture formats and designed as endpoint  tests17. Some efforts toward assay 
validation in 3D monocultures are reported in the literature. Huber et al. analyzed cell viability, necrosis and 
proliferation in spheroids of a lung cancer cell line challenged with afatinib, cisplatin or vinorelbine. The authors 
adapted ATP, LDH and annexin V/propidium iodide (PI) staining, microscopic volume/diameter assessment 
and cell cycle analyses to 3D spheroid cultures. They highlighted the need for assay adaptation for each type of 
3D culture, namely determination of total intra- and extra-cellular ATP and LDH  content18.
The architectural complexity and heterogeneous content associated with 3D cultures also pose a challenge for 
cytotoxic assays to accurately report treatment  outcomes19. Among common readout methods, the LDH assay, 
volume measurements, fluorescence and luminescence measurements of reporter protein-expressing cells have 
the benefit of longitudinal culture monitoring, enabling data collection without sacrificing the integrity of the 
sample. Unfortunately, the generation of luciferase-expressing cancer cells from the patient material will result 
in the loss of essential stromal and ECM components as well as the selection of a subpopulation of cancer cells, 
eliminating the heterogeneity that is crucial to modeling clinical  responses20–22. Volume measurements are also 
limited in their inability to distinguish between live and dead cells and to account for the presence of necrotic 
areas within the spheroids, further restricting assessments of cell  viability23.
We, therefore, endeavored to determine the utility of the LDH assay to analyze complex 3D cultures, particu-
larly those derived from patient tumor tissues. LDH is a cytosolic enzyme released into the cell culture medium 
upon plasma membrane leakage, indicating cell  toxicity24. LDH release has been used successfully to measure 
cell growth and viability in multicellular spheroids and bioreactor 3D culture  systems25–28. However, standard 
protocols for accurate and reproducible quantification of therapeutic effects in complex ex vivo cultures, such 
as explant models, have yet to be described. We demonstrate the value of the LDH assay through measurements 
of cell growth and viability in spheroid cultures and cytotoxic agent efficacy in ex vivo cultures compared to 
other standard readout methods. Using spheroids, we showed that LDH assay measurements of cell growth and 
viability directly correlated with volume measurements, the CTG-3D assay, and luminescence measurements of 
luciferase-expressing cells. Spheroid cultures were used to generate sufficient sample number and uniformity. 
The confirmation of reliable and sensitive cell content measurements via the LDH assay in spheroid cultures, a 
basic 3D culture format, enabled us to expand its application to more complex models.
We used simulated data to assess the impact of culture dynamics on the determination of drug-induced cell 
death by LDH assay. Overall, cell growth and death dynamics and background LDH release might impact the 
accurate determination of cell death. Culture dynamics must be well characterized before the LDH assay can be 
effectively applied to complex culture systems. The culture format and objective of the drug-induced cell death 
evaluation will dictate the most appropriate method of data collection and analysis. If cultures are longitudinally 
monitored but have background levels of LDH or high rates of cell death, accurate IC50 values cannot be deter-
mined unless both control and treated samples are lysed (Eq. 5). Although drug-induced cell death based on 
CM samples and control group lysate (Eq. 3) may hinder the determination of precise IC50 during longitudinal 
culture monitoring, differences in therapeutic efficacy between treatment groups can still be determined, making 
stack ranking of compound efficacy a possibility.
We first applied the LDH assay to xenosphere cultures derived from NCI-H1650 and NCI-H1650.LMC xeno-
grafts treated with DTX. We demonstrated that the LDH assay is as effective as other commercially available cell 
viability readouts at determining therapeutic efficacy. The availability of cell line-derived xenografts for xeno-
sphere generation is much less restricted than patient material, thus preserving the biological material is not as 
 crucial7,29–31. When applied to the patient-derived culture system, the LDH assay captured a range of therapeutic 
responses, with the additional benefit of longitudinal culture monitoring. We further observed that variations in 
drug-induced cell death were best captured by the LDH assay compared to clinically utilized endpoint readouts 
(H&E and IHC). Although chemotherapeutic agents target cancer cells (epithelial compartment), widespread 
cell death in both epithelial and stromal compartments might occur, contributing to an overall decrease of tumor 
burden, which is not captured by the epithelial compartment ratio determined by H&E analysis. Moreover, H&E 
and IHC analyses are highly dependent on the cellular and tissue integrity at the end of the culture. In most OvC 
cases, after two drug cycles, few or no tumor cells were observed, which hinders the application of these readouts. 
Determinations of therapeutic efficacy might also be inaccurate using endpoint-based methods in long-term 
drug exposure assays since the remaining cells could represent a resistant population. In these situations, cell 
death and further detachment cannot be considered over the culture period.
Conclusions
Altogether, the LDH assay is a suitable method for longitudinal monitoring and endpoint analysis of therapeutic 
efficacy in complex 3D in vitro tumor models, such as tumor spheroids, xenospheres and PDE. Moreover, it is not 
dependent upon the integrity of the sample at the experimental endpoint. However, culture dynamics limit the 
accuracy of drug-induced cell death determined by longitudinal measurements and must be considered when 
making conclusions of therapeutic efficacy. The development of standardized protocols to apply compatible read-
out methods, like the LDH assay, to complex 3D culture systems could greatly benefit preclinical and co-clinical 
studies. Reliable readout methods will enable the use of complex in vitro cultures, such as xenospheres, to test 
therapies targeting the tumor microenvironment or eliminate therapies that are likely to show no efficacy in vivo 
due to resistance mechanisms that can only be captured in a more complex culture system than the traditional 
 monolayer32–34. The use of such culture systems in early drug discovery could save vast amounts of resources 
in the form of time and money. This study also demonstrated that the LDH assay applied to PDE cultures can 
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recapitulate sample-specific response variability to SOC chemotherapeutic drugs and is suitable to study combi-
natorial effects of drug combinations. Even though further prospective studies should be performed to evaluate 
the prediction capability of the PDE cultures, this study foresees the broader application of LDH assay method-
ology as a therapeutic efficacy tool in future co-clinical assays for precision medicine and patient stratification.
Methods
3D culture generation. Cell culture. Lung adenocarcinoma NCI-H1650 (ATCC, Manassas, VA) and 
NCI-H1650.LMC cells (NCI-H1650 cells transduced with luciferase and mCherry) were cultured in RPMI 1640 
cell culture medium (Gibco, Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS, Fisher Sci-
entific, Waltham, MA) and 1% penicillin/streptomycin (P/S, Fisher Scientific, Waltham, MA). To generate the 
NCI-H1650.LMC line, a fusion construct of luc2 (Promega, Madison, WI) and mCherry (Clontech, Mountain 
View, CA) was cloned into the Lenti-X lentiviral vector (Clontech). NCI-H1650 cells were transduced with 
lentiviral particles for 48 h and a pool of cells stably expressing the fusion construct were selected using 2 µg/
ml puromycin for 2 weeks. All cultures were maintained in a 37 °C humidified incubator with 5%  CO2. In all 
experiments, cells with less than 10 passages after thawing were used.
Spheroids. Spheroid generation. A suspension of NCI-H1650 and NCI-H1650.LMC cells were seeded 
at 2500, 5000, 7500, 10,000, 12,500, and 15,000 cell/well of 96-well ultra-low attachment round bottom plates 
(Corning, Corning, NY), in 200 µl of culture medium per well. Plates were subsequently centrifuged at 335 × g 
for 5 min and cultured up to 7 days in a 37 °C humidified incubator with 5%  CO2.
Xenospheres. Xenosphere generation. NCI-H1650 and NCI-H1650.LMC cells suspended in culture me-
dium were mixed (1:1) in Matrigel (Corning, Corning, NY). Five million cells in a total volume of 100 µl were 
injected subcutaneously in the right flank of ten female SCID-beige mice for each cell type (Charles River Labo-
ratory, Wilmington, MA). Xenografts were collected when tumors reached a volume of 200–300  mm3. Excised 
tumors were placed in serum-free RPMI 1640 culture medium in a glass petri dish. Tumors were cut into pieces 
of approximately 500–600 µm using sterile scalpels and guided by the reticle of an Olympus SZX9 microscope 
(Olympus Life Science, Tokyo, Japan). Individual xenospheres were directly transferred into a single well of an 
ultra-low attachment round bottom 96-well plate and cultured in 200 µl of RPMI 1640 culture medium sup-
plemented with 10% FBS and 1% P/S. Xenospheres were cultured up to 7 days in a 37 °C humidified incubator 
with 5%  CO2.
Animal husbandry. Seven-week-old mice were obtained from Charles River (Wilmington, MA). Ten mice were 
housed per cage. The body weight upon arrival was 18–20 g. Food and water were available ad libitum. Mice were 
acclimated to the animal facilities for a period of at least 1 week prior to the commencement of experiments. 
Animals were tested in the light phase of a 12-h light: 12-h dark schedule. Mice were individually tagged and 
assigned to numbered cages. At the study endpoint, animals were humanely euthanized via isoflurane inhalation 
followed by exsanguination. All experiments were conducted in compliance with AbbVie’s Institutional Animal 
Care and Use Committee and the National Institutes of Health Guide for Care and Use of Laboratory Animals 
guidelines in a facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal 
Care (AAALAC). All methods are reported in accordance with ARRIVE guidelines.
PDE. Study sample. Consent to fresh surgically removed tumors from 16 patients with OvC who underwent 
surgery at Instituto Português de Oncologia de Lisboa, Francisco Gentil (IPOLFG) was obtained from 2018 to 
2020. Tumor specimens were transported in DMEM culture medium from the surgery room to the laboratory. 
Samples were named chronologically from OvC1 to OvC16 (Supplementary Table 7).
Sample collection and processing. Fresh (up to 4 h) surgically removed tumor specimens were weighed and 
mechanically dissociated into fragments of approximately 1  mm2 as recently described by our  team13.
Cell viability assays in spheroid cultures. Cell viability assays were performed on days 0 (day after seed-
ing) and 7 of spheroid culture.
Volume measurements. Brightfield images of spheroids were collected on a Nikon Eclipse Ti at 4x. Area of the 
imaged spheroid section was determined by ImageJ analysis. Volume was calculated as:
LDH assay. LDH activity was measured using the Pierce LDH Cytotoxicity Assay Kit following the manufac-
turer protocol (ThermoFisher Scientific, Waltham, MA). Briefly, 50 µl of conditioned medium (CM) was col-
lected from each sample. The cells were lysed using 10 µl of the lysate buffer provided in the assay kit, for 45 min 
at 37 °C and 50 µl of lysed cells were collected from each sample. The LDH assay was run on the CM and lysate 
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CTG‑3D assay. ATP content in spheroid cultures was assessed using a CTG-3D Cell Viability Assay (Promega, 
Madison, WI) following the manufacturer protocol. Luminescence was measured on a SpectraMax iD5.
Luminescence measurements. Luminesce measurements were taken from NCI-H1650.LMC spheroid cultures. 
A 15 mg/ml solution of D-luciferin potassium salt [PerkinElmer, Waltham, MA] in sterile phosphate-buffered 
saline (PBS, Fisher Scientific, Waltham, MA) was added to each sample medium to generate a final luciferin 
concentration of 1.5 mg/ml. Samples were protected from light and placed in a 37 °C, 5%  CO2 incubator for 1 h. 
Luminescence of each sample was measured on a SpectraMax iD5.
Assessment of spheroid culture growth. We utilized a normalized growth rate equation adapted from Hafner 
et al.35: to determine growth rate inhibition following drug treatments, to compare cell growth in the spheroid 
cultures as determined by each readout method
Instead of cell number as previously described,  x0, ro and  xro represent the cell content at the beginning and 
end of the experiment, respectively, as determined by the readout method of interest.  X0, ctrl and  xctrl represent 
the cell content at the beginning and end of the experiment, respectively, as determined by a control readout. 
Absorbance, luminescence, or volume measurements at assay timepoints were used to measure cell content. 
Volume measurements were used as the control readout method.
LDH assay simulation. LDH data was simulated to determine how growth rate and background LDH 
release in untreated samples may impact the evaluation of therapeutic efficacy in 3D cultures. Values for LDH 
content in the cell lysate and CM were generated to reflect cases of no growth or cell tripling over 7 days in 
culture with 0% or 10% background LDH release following treatments that induce 0–80% cell death over the 
culture period (7 days) or daily. Drug-induced cell death values were simulated by three equations:
where total LDH is the sum of the CM and lysate LDH values.
According to the manufacturer protocol, only CM and lysate from the control group should be considered 
(Eq. 3). To address cell growth and LDH background release, lysates from control and treated groups were con-
sidered together with the CM (Eq. 4) or only lysate content was considered (Eq. 5).
SOC therapeutic efficacy in ex vivo cultures. Assessment of DTX efficacy in xenosphere cultures. DTX 
(Sigma-Aldrich, St. Louis, MO) treatments of control, 0.1, 5, 25, 125, 625, and 3125 nM were added to xeno-
spheres on the day of xenosphere generation (day 0). Samples were treated for 7 days. DTX efficacy was assessed 
in NCI-H1650 xenospheres via volume measurements, LDH assay, and CTG 3D assay. DTX efficacy was as-
sessed in NCI-H1650.LMC xenosphere cultures via volume and luminescence measurements. Control samples 
on day 0 were also assessed via the cell line’s respective readout methods. All readout methods were carried out 
as described previously for the spheroid cultures. The half-maximal inhibitory concentration (IC50) values were 
determined by four-parameter variable slope logistic regression analysis of the concentration-response data.
Drug challenge in PDE cultures. Drug challenges were conducted in PDE cultures of 10 PDE/well in 12 well 
plates at a concentration of 5 PDE/ml under orbital agitation at 100  rpm. OvC-PDE cultures from different 
OvC subtypes were challenged weekly with SOC chemotherapy, namely carboplatin (25 mg/ml) or paclitaxel 
(10 mg/ml) as single agents or in  combination13,36,37. Briefly, after 7 days of culture, the medium of all wells was 
exchanged and OvC-PDE were challenged with single agents or a pre-mixed drug combination for 1 week. At 
the end of the first drug cycle (day 14 of culture), a complete exchange of medium followed by a second drug 
challenge for one additional week was performed (until day 21 of culture). Cell death was assessed longitudinally 
(day 7, 14, and 21 of culture) by LDH assay. Additionally, morphology and quantification of epithelial (malignant 
tumor cells) and stromal compartments were assessed by histopathological analysis and proliferation and apop-
tosis levels by immunohistochemistry.
Cell death evaluation by LDH assay in PDE cultures. CM was collected from each sample on days 7, 14, and 21 
of culture. At each timepoint, PDE from at least one control well were lysed with 10% triton X-100 for 24 h. Cul-
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from all CM conditions. Following CM collection, samples were centrifuged at 1000 × g for 5 min, at 4 °C, and 
stored at 4 °C until further analysis (up to 3 days). For the LDH assay, 50 µl of each sample (previously diluted 
in PBS to ensure an absorbance measurement within the linear range) was transferred to a 96-well flat-bottom 
plate in technical duplicates. The LDH assay was performed as described above. To calculate % drug-induced cell 
death, the following equation was used:
Histopathological analysis. The morphology of parent patient tumor tissue was compared with the correspond-
ing OvC-PDE at day 0 of culture (after processing) and at the end of the culture (day 21). Samples were processed 
for H&E staining and quantified as previously  described13.
IHC analysis. Proliferation and apoptosis levels of original OvC tumors were compared with corresponding 
OvC-PDE on day 0 of culture (after processing) and at the end of the culture (day 21). OvC-PDE from untreated 
control and drug-treated conditions were also assessed at the end of the drug challenge (day 21 of culture). Sam-
ples were processed and analyzed as previously  described13. The predominant intensity of staining was recorded 
on a scale of 0–100%, divided into six bins: < 1, 1–5, 5–25, 25–50, 50–75, > 75%. Median bin values, assessed at 
the end of drug challenge (day 21 of culture), were considered for further comparison of untreated controls and 
drug-treated conditions.
Statistical analysis. Statistical analysis was performed using one-way ANOVA, Tukey’s test for multiple 
comparisons, Sidak’s test for multiple comparisons, Pearson correlation analysis, and Wilcoxon signed-rank sta-
tistical test. GraphPad Prism version 7.05 software was used for all analysis. Results were considered statistically 
significant for p < 0.05 and were expressed as mean ± standard deviation (SD).
Ethics approval and consent to participate. The animal studies and all procedures involved were 
approved by the AbbVie’s Institutional Animal Care and Use Committee, in compliance with the rules of the 
National Institutes of Health Guide for Care and Use of Laboratory Animals guidelines. All procedures per-
formed in studies involving human participants were in accordance with the ethical standards of the institu-
tional and/or national research committee. Informed consent was obtained from all individual participants prior 
to the enrollment in the study. Anonymized patient tumor samples were obtained from the IPOLFG after insti-
tutional review board approval. The project was approved by the Research Council of IPOLFG and by the Ethics 
Committee for Health of IPOLFG (UIC-1088 and UIC-1211).
Consent for publication. All authors have given consent for publication.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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